Study of RG002 vaccine for HPV-related cervical precancer
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This study tests a new injection (RG002) for women with a cervical precancer called CIN 2 or CIN 3 that is caused by HPV types 16 or 18. The goal is to see if the treatment can help the body clear the precancer without needing surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old (for Part A) or 18 to 55 (for Part B).
- You have a cervical precancer called CIN 2 or CIN 3 that was confirmed by a biopsy in the last 12 weeks.
- You have HPV type 16 or 18 (a high-risk type), which is causing the precancer.
- Your BMI is 30 or less.
- You are not pregnant or breastfeeding, and you agree to use effective birth control for 9 months after the last injection.
- You have not had a past HPV treatment vaccine (the standard HPV prevention shot is okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine called PVX4 for women with HPV16-related cervical dysplasia. It aims to see if the vaccine can help clear the high-risk HPV infection and the abnormal cells on the cervix.
This trial tests a new vaccine (RG1-VLP) designed to prevent HPV-related cancers. It is for healthy women who have not been vaccinated against HPV before and are willing to receive three doses of the vaccine over several months.
This trial tests a new vaccine (SYS6026) for women with high-grade cervical lesions caused by HPV type 16 or 18. It aims to see if the vaccine can help the body clear these precancerous cells, potentially avoiding surgery.
This trial tests an experimental shot, BBM-C101, for women with a specific type of cervical pre-cancer caused by HPV types 16 or 18. The goal is to see if the shot is safe and can help the body fight the infection, possibly eliminating the abnormal cells.
This early-phase study tests a vaccine designed to help your immune system fight HPV16, a type of human papillomavirus linked to abnormal cells in the cervix. You may or may not be living with HIV, and the team will check safety and immune response after giving the vaccine in a specific way.
This trial tests a new injection called BBM-C101 for people with a long-lasting HPV16 or HPV18 infection that hasn't gone away with other treatments, or who choose not to have surgery. The goal is to see if the vaccine can help the body clear the virus and prevent precancerous changes from getting worse.
Hear when a new Cervical Intraepithelial Neoplasia Grade 2/3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.